Amber Therapeutics, a developing a closed-loop neuromodulation therapy, completed the acquisition of Bioinduction, a medical laboratory. Financial terms were not disclosed. “We are very excited to announce the acquisition of Bioinduction and its Picostim-DyNeuMo platform. Our teams worked together developing the platform from concept to first-in-human trials in under two years. This deal formally brings together an experienced group of professionals with decades of design, clinical and manufacturing experience, who can now focus on taking our first therapy to market.” Aidan Crawley, Amber CEO.